



an Open Access Journal by MDPI

Emerging Trends in Lipoprotein and Cardiovascular Diseases

Guest Editors:

Prof. Dr. Yong-Jae Lee

Department of Family Medicine,
Yonsei University College of
Medicine, Seoul, Republic of
Korea

Dr. Byoungjin Park

Department of Family Medicine,
Yonsei University College of
Medicine, Seoul 03722, Republic
of Korea

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editors

Dear Colleagues,

High-density lipoproteins (HDL) have a unique lipid metabolism status, and have important clinical implications as biomarkers. It is well known that low HDL cholesterol is a risk factor for atherosclerotic cardiovascular disease; however, many clinical concerns require further investigation. HDL cholesterol interacts, directly or indirectly, with various substances in the blood, as well as with other lipids. Furthermore, HDL cholesterol has several subclasses, and additional research is required to better understand how they work differently to cardiometabolic health issues. Furthermore, detailing implications according to gender, ethnicity, age group, and interrelationships with drugs and nutrition will also be critical biomedical aspects to consider in clinical settings. Beyond the conventional understanding of HDL cholesterol, it is time for advanced research pertaining to technological advances in various clinical contexts. We encourage worldwide participation from researchers interested in cardiovascular and metabolic health.



mdpi.com/si/114908

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)